Table 3.
Clinicopathological characteristics of breast cancers according to neutrophil-to-lymphocyte ratio (NLR) or c-reactive protein/albumin ratio (CAR) levels.
| Characteristics | NLR | p-Value | CAR | p-Value | ||
|---|---|---|---|---|---|---|
| NLR<2.2 (n=423) | NLR≥2.2 (n=285) | CAR<0.07 (n=610) | CAR≥0.07 (n=98) | |||
| Age (years) | 0.001 | 0.001 | ||||
| <50 | 185 (43.7%) | 161 (56.5%) | 316 (51.8%) | 30 (30.6%) | ||
| ≥50 | 238 (56.3%) | 124 (43.5%) | 294 (48.2%) | 68 (69.4%) | ||
| BMI | 0.305 | 0.001 | ||||
| <24 | 260 (61.5%) | 186 (65.3%) | 403 (66.1%) | 43 (43.9%) | ||
| ≥24 | 163 (38.5%) | 99 (34.7%) | 207 (33.9%) | 55 (56.1%) | ||
| Menopausal status | 0.01 | 0.001 | ||||
| Pre- | 200 (48.4%) | 162 (58.7%) | 327 (55.1%) | 35 (36.8%) | ||
| Post- | 213 (51.6%) | 114 (41.3%) | 267 (44.9%) | 60 (63.2%) | ||
| Tumor size | 0.283 | 0.066 | ||||
| <2cm | 275 (65.0%) | 174 (61.1%) | 395 (64.8%) | 54 (55.1%) | ||
| ≥2cm | 148 (35.0%) | 111 (38.9%) | 215 (35.2%) | 44 (44.9%) | ||
| Lymph node metastasis | 0.108 | 0.001 | ||||
| Negative | 370 (87.5%) | 237 (83.2%) | 535 (87.7%) | 72 (73.5%) | ||
| Positive | 53 (12.5%) | 48 (16.8%) | 75 (12.3%) | 26 (26.5%) | ||
| TNM grade | 0.093 | 0.001 | ||||
| I | 257 (60.8%) | 165 (57.9%) | 377 (61.8%) | 45 (45.9%) | ||
| II | 137 (32.4%) | 87 (30.5%) | 190 (31.1%) | 34 (34.7%) | ||
| III | 29 (6.9%) | 33 (11.6%) | 43 (7.0%) | 19 (19.4%) | ||
| Histology type | 0.444 | 0.006 | ||||
| Infiltrating ductal carcinoma | 374 (88.6%) | 261 (91.6%) | 553 (90.7%) | 82 (84.5%) | ||
| Infiltrating lobular carcinoma | 10 (2.4%) | 5 (1.8%) | 15 (2.5%) | 0 (0) | ||
| Others | 38 (9.0%) | 19 (6.7%) | 42 (6.9%) | 15 (15.5%) | ||
| Luminal subtype | 0.116 | 0.549 | ||||
| Luminal A | 199 (47.0%) | 117 (41.1%) | 275 (45.1%) | 41 (41.8%) | ||
| Luminal B | 224 (53.0%) | 168 (58.9%) | 335 (54.9%) | 57 (58.2%) | ||
| Operation type | 0.216 | <0.001 | ||||
| Modified radical mastectomy | 225 (53.2%) | 150 (52.6%) | 314 (51.5%) | 61 (62.2%) | ||
| Breast-conserving surgery | 147 (34.8%) | 102 (35.8%) | 226 (37.0%) | 23 (23.5%) | ||
| Mammectomy | 47 (11.1%) | 25 (8.8%) | 64 (10.5%) | 8 (8.2%) | ||
| Others | 4 (0.9%) | 8 (2.8%) | 6 (1.0%) | 6 (6.1%) | ||
| Chemotherapy | 0.009 | 0.09 | ||||
| Neoadjuvant chemotherapy | 32 (7.6%) | 34 (11.9%) | 51 (8.4%) | 15 (15.3%) | ||
| Adjuvant chemotherapy | 206 (48.7%) | 156 (54.7%) | 315 (51.6%) | 47 (48.0%) | ||
| No chemotherapy | 185 (43.7%) | 95 (33.3%) | 244 (40.0%) | 36 (36.7%) | ||
| Radiotherapy | 0.175 | 0.811 | ||||
| No | 194 (45.9%) | 116 (40.7%) | 266 (43.6%) | 44 (44.9%) | ||
| Yes | 229 (54.1%) | 169 (59.3%) | 344 (56.4%) | 54 (55.1%) | ||
All of our variables with p-values less than 0.05 are in bold.